



Original Investigation | Cardiology

Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care

Nils Krüger, MD; Johannes Krefting, MD; Thorsten Kessler, MD; Raphael Schmieder, MD; Fabian Starnecker, MD; Alexander Dutsch, MD; Christian Graesser, MD; Ulrike Meyer-Lindemann, MD; Theresa Storz, MD; Irina Pugach, PhD; Christian Frieß, MD; Zhifen Chen, PhD; Dario Bongiovanni, MD; Iulian Manea, BSc; Tobias Dreischulte, PhD; Frank Offenborn; Peter Krase; Hendrik B. Sager, MD; Jens Wiebe, MD; Sebastian Kufner, MD; Erion Xhepa, MD, PhD; Michael Joner, MD; Teresa Trenkwaller, MD; Ulrich Gueldeiner, PhD; Adnan Kastrati, MD; Salvatore Cassese, MD; Heribert Schunkert, MD; Moritz von Scheidt, MD; for the DigiMed Bayern Consortium

Abstract

IMPORTANCE In patients with acute coronary syndrome (ACS) undergoing invasive treatment, ticagrelor and prasugrel are guideline-recommended P2Y₁₂ receptor inhibitors. The ISAR-REACT5 randomized clinical trial demonstrated superiority for prasugrel, although concerns were raised about the generalizability of some underpowered subgroup analyses.

OBJECTIVES To emulate a randomized clinical trial evaluating the safety and effectiveness of ticagrelor vs prasugrel under the conditions of routine care in individuals with ACS planned to undergo an invasive treatment strategy.

DESIGN, SETTING, AND PARTICIPANTS This new-user cohort study included secondary data from a German statutory health insurance claims database between January 2012 and December 2021, using 1:1 propensity score nearest-neighbor matching to emulate ISAR-REACT5. Individuals with ACS receiving either ticagrelor or prasugrel treatment after hospital discharge were followed up for 1 year. Eligibility criteria closely emulated those of ISAR-REACT5 and included age of 18 years or older and cardiovascular risk factors. Data were analyzed from May 2023 to May 2024.

EXPOSURE Outpatient prescription of ticagrelor or prasugrel.

MAIN OUTCOMES AND MEASURES The primary end point was the composite of all-cause mortality, myocardial infarction (MI), or stroke within 1 year of outpatient treatment initiation. Secondary end points included individual components of the primary end point and stent thrombosis. The safety end point was major bleeding. A Cox proportional hazards regression model was fitted to the overall cohort.

RESULTS Of 17 642 propensity score-matched individuals (mean [SD] age, 63.1 [10.9] years; 73.9% male), 8821 received ticagrelor and 8821 received prasugrel. Agreement was met in 11 of 12 predefined agreement metrics when comparing the results with ISAR-REACT5. The primary composite end point of all-cause mortality, MI, or stroke occurred in 815 individuals (9.2%) receiving ticagrelor and 663 (7.5%) receiving prasugrel (hazard ratio [HR], 1.24; 95% CI, 1.12-1.37). Myocardial infarction (HR, 1.20; 95% CI, 1.06-1.36) and stroke (HR, 1.33; 95% CI, 1.02-1.74) each occurred significantly more often in the ticagrelor group. Analysis of all-cause mortality (HR, 1.27; 95% CI, 0.99-1.64), stent thrombosis (HR, 1.11; 95% CI, 0.89-1.30), and major bleeding (HR, 1.12; 95% CI, 0.96-1.32) revealed no significant differences between treatment groups. Subgroup analysis showed that prasugrel was associated with the primary composite end point in fewer individuals with ST-segment elevation MI (338 of 4941 [6.8%] vs 451 of 4852 [9.3%]).

(continued)

Key Points

Question In routine clinical care, when compared with ticagrelor, is prasugrel associated with improved cardiovascular outcomes among individuals with acute coronary syndrome?

Findings In this cohort study of 17 642 propensity score-matched individuals, compared with ticagrelor, prasugrel was associated with a significantly lower incidence of the primary composite end point of all-cause mortality, myocardial infarction, or stroke.

Meaning In routine care, prasugrel was associated with improved outcomes, supporting its preferred use in the treatment of acute coronary syndrome in individuals undergoing an invasive treatment strategy.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Abstract (continued)

CONCLUSIONS AND RELEVANCE This cohort study found that prasugrel was associated with lower rates of all-cause mortality, MI, or stroke compared with ticagrelor in individuals with ACS undergoing an invasive treatment strategy in routine care, particularly in individuals with ST-segment elevation MI. The findings suggest that carefully designed database studies can complement and extend findings from randomized clinical trials, informing guidelines and clinical decision-making.

JAMA Network Open. 2024;7(12):e2448389.

Corrected on January 17, 2025. doi:10.1001/jamanetworkopen.2024.48389

Introduction

The optimal treatment choice between the P2Y₁₂ receptor inhibitors ticagrelor and prasugrel for acute coronary syndrome (ACS) remains debated in the context of dual-antiplatelet therapy, as randomized clinical trials (RCTs) comparing the 2 agents are limited and were inconclusive.¹⁻³ The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-5 (ISAR-REACT5 [IR5]) RCT¹ compared ticagrelor and prasugrel for treatment of ACS in patients planned for an invasive treatment strategy. Prasugrel demonstrated superior efficacy over ticagrelor in the reduction of the primary composite end point of all-cause mortality, nonfatal myocardial infarction (MI), or nonfatal stroke.¹ For the safety end point, defined as major bleeding, the trial observed no statistically significant difference between the 2 agents.

The Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction (PRAGUE-18) RCT compared ticagrelor with prasugrel in patients with acute MI.^{2,3} Its primary composite end point (all-cause death, MI, stroke, major bleeding requiring transfusion, or prolongation of hospitalization) did not differ significantly between the agents at the 7-day or 1-year follow-up. However, interpretation was limited due to underpowering, with approximately 40% of the study population switching to clopidogrel after hospital discharge likely due to patients having to cover the costs of the more expensive study medication.

Subsequent to the trials, in 2023, the European Society of Cardiology implemented a modest guideline recommendation favoring prasugrel over ticagrelor for patients with ACS who proceed to percutaneous coronary intervention (PCI) (class IIa, level B).⁴ In contrast, the American College of Cardiology and American Heart Association guideline recommends both drugs equally in combination with aspirin.⁵

Regulatory agencies in Europe and the US increasingly recognize and reevaluate the value of evidence derived from observational data to guide regulatory decision-making⁶⁻⁸ by overseeing and promoting comparative analyses.^{9,10} Given the ongoing debate and limited evidence for the optimal treatment choice between ticagrelor and prasugrel in the treatment of ACS,¹¹ we aimed to estimate the causal effects of the 2 drugs using observational data from insurance claims. By emulating IR5, we aimed to evaluate whether the evidence generated in the present study would support the same regulatory and clinical conclusions as the trial.

Methods

Study Design

In this study, a new-user cohort design was used with the aim of emulating IR5¹ as closely as possible in claims data by creating observational analogues for the population, intervention, comparator, outcome, and timing (PICOT) criteria that define the trial's research question. This included aligning time 0 with the target trial. In IR5, cohort entry was the day that patients were randomized during hospitalization. However, as claims data do not include information on inpatient medication, cohort entry was therefore defined as the time of the first observed outpatient initiation of ticagrelor or

prasugrel after ACS. To account for lack of randomization, 1:1 propensity score nearest-neighbor matching was performed on preexposure characteristics measured in the year prior to the ACS event.^{12,13} These characteristics were compiled from IR5 baseline information,¹ potential confounders from the literature,^{1,14,15} and the investigators' clinical expertise. They included baseline demographics, cardiovascular risk factors, ACS type, medical procedure type, and time of ACS (eTable 3 in [Supplement 1](#)). A study protocol, including a detailed analysis plan for emulation of the trial eligibility criteria, was developed a priori before analyses were conducted and was registered at the World Health Organization's linked German Registry of Clinical Studies to allow a structured, transparent, and reproducible implementation process. Approval for the current study was granted by the ethics committee of the Technical University Munich. Informed consent was waived because data were deidentified. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Population

Eligibility criteria of IR5¹ were emulated closely (eTable 2 in [Supplement 1](#)). Inclusion criteria were age of 18 years or older and an *International Statistical Classification of Diseases, Tenth Revision, German Modification (ICD-10-GM)* code for ACS (ST-segment elevation MI [STEMI], non-STEMI [NSTEMI], or unstable angina [UA]). These codes were internally validated by requiring an invasive assessment with diagnostic cardiac catheterization, PCI, or coronary artery bypass graft surgery (CABG) within 3 days of ACS diagnosis. Exclusion criteria reflecting the target trial were applied thereafter (eTable 2 in [Supplement 1](#)). Individuals who were dispensed ticagrelor or prasugrel within 180 days before the ACS event were excluded from the study. Furthermore, continuous enrollment in the database for at least 12 months prior to study entry was required to assess baseline covariates.

Intervention, Comparator, Outcome, and Timing

Individuals were assigned to their respective treatment group according to their first observed out-of-hospital prescription fill for ticagrelor or prasugrel no later than 14 days after an ACS event. Emulating IR5, the primary end point was the composite of all-cause mortality, MI, or stroke. Secondary end points were individual components of the primary end point as well as stent thrombosis. The safety end point was major bleeding. All outcome variables are provided in eTable 1 in [Supplement 1](#). Individuals were followed up from the date of the first observed outpatient prescription of ticagrelor or prasugrel after ACS diagnosis until 1 year.

In alignment with the intention-to-treat analysis used in IR5, all individuals were analyzed according to their treatment assignment regardless of adherence to the study drugs. To assess in-hospital mortality, which was not included in the primary analysis to avoid immortal time, we evaluated mortality in the entire cohort with ACS within the mean duration between ACS diagnosis and the initial outpatient prescription of the P2Y12 receptor inhibitor.

Data Source and Implementation Process

German claims from the statutory health insurance database Allgemeine Ortskrankenkasse Bayern between January 2012 and December 2021, as part of the Observational Bavarian Health Insurance Registry, were used.¹⁶ The database contains deidentified demographics and information for covered health care encounters including inpatient and outpatient diagnoses, medical procedures, community-dispensed prescriptions, and vital status information (eTable 1 in [Supplement 1](#)).

Subgroup Analyses

To address subgroups for whom results remained inconclusive in IR5, we performed a detailed analysis on the distinct ACS conditions: STEMI, NSTEMI, and UA. The aim was to identify differential responses to treatment and inform therapeutic strategies accordingly.

Predefined Binary Agreement Metrics Between Database Study and RCT Results

To evaluate whether the database study would support the same regulatory and clinical conclusions as IR5, 2 predefined binary metrics were used to compare the results. First was regulatory agreement, defined by both the hazard ratio (HR) and 95% CI being on the same side of 1; second was estimate agreement, defined by the HR for the database study falling within the 95% CI of the RCT, as there may have been cases in which the current study found a statistically significant association due to substantially higher power but the RCT failed to find statistical significance.¹⁷

On-Treatment Analysis

To mimic high adherence patterns observed in RCTs, an on-treatment design was used. This analysis defined the time from the date of the first observed outpatient initiation of the study drugs to the time of discontinuation, treatment switch, or an end point. Adherence to study medication was assessed indirectly based on pharmacy prescription fills.

Sensitivity Analysis

To evaluate the robustness of the analysis for the primary end point and address potential residual confounding, preexposure characteristics were extended for propensity score matching. Along with demographics, lifestyle factors, and comorbidities, we also considered disease-specific variables, including the use of cardiovascular and other medications, cardiovascular procedures, and health care utilization indicators. These indicators served as proxies for the overall disease state, care intensity, and surveillance (eTable 4 in [Supplement 1](#)).

To assess potential net bias from residual confounding, measurement issues, or follow-up criteria, influenza was used as a negative control outcome. Observed prescription fills for aspirin within 14 days of ACS diagnosis were computed for both groups.

Statistical Analysis

Propensity score matching was conducted to balance confounders between the treatment groups. We used a 1:1 nearest-neighbor method with a 1% caliper based on the preexposure characteristics (eTables 3 and 4 in [Supplement 1](#)).

Kaplan-Meier survival curves were constructed for the treatment groups using the Kaplan-MeierFitter class from the lifelines package in Python, version 3.11.6 (Python Software Foundation).¹⁸ Respective survival functions were plotted. For nonfatal outcomes, the Aalen-Johansen method, as implemented in the lifelines package, together with the packages survival and cmprsk in RStudio, version 4.1.2 (RStudio, PBC), were used to account for competing risks, as in IR5.¹

A Cox proportional hazards regression model was fitted to the overall cohort that included follow-up times, censoring indicators, and treatment group. Treatment was included as the only variable of interest. Results were reported as HRs and 95% CIs. The proportional hazards assumption was tested by examining log-log survival plots. Additionally, to statistically assess the validity of the proportional hazards assumption, Schoenfeld residuals were calculated and tested for any correlation with time using the cox.zph function from the survival package in R, version 4.1.2. All analyses were conducted from May 2023 to May 2024 using Python, version 3.11.6¹⁹ and RStudio, version 4.1.2.²⁰

Results


Of 131 760 individuals in the database with ACS who underwent an invasive treatment strategy, 27 723 (21.0%) were treated with ticagrelor or prasugrel and met the emulated IR5 eligibility criteria. After propensity score matching, 17 642 matched individuals (8821 in each group) remained (**Figure 1, Table 1**). Mean (SD) age was 63.1 (10.9) years; 73.9% were men, and 26.1% were women. ACS types included STEMI (9793 individuals [55.5%]), NSTEMI (6558 [37.2%]), and UA (1291 [7.3%]). Individuals were almost exclusively treated with PCI (98.5%); 0.2% received CABG, and 1.3%

received conservative treatment. For the ticagrelor group, the median follow-up was 12.0 months (IQR, 12.0-12.0 months; mean [SD], 10.7 [3.2] months); for the prasugrel group, the median follow-up was 12.0 months (IQR, 12.0-12.0 months; mean [SD], 10.8 [3.0] months).

Of the 23 inclusion criteria from IR5, the present study was able to directly emulate 13 (56.5%) and indirectly emulate 7 (30.4%); it left 3 (13.0%) unmet. Similarly, of the 19 exclusion criteria, 6 (31.6%) were met directly, 1 (5.3%) was met indirectly, and 12 (63.2%) remained unmet (eTable 2 in Supplement 1). Differences in the measurement of some key study parameters were found when close observational analogues to trial design elements could not be identified due to differences in the type of data collected.

At 1-year follow-up, the primary end point (all-cause mortality, MI, or stroke) occurred in 815 individuals in the ticagrelor group (9.2%) vs 663 in the prasugrel group (7.5%; HR, 1.24; 95% CI, 1.12-1.37). Secondary end points in the ticagrelor vs prasugrel groups, respectively, included all-cause mortality in 135 (1.5%) vs 106 (1.2%; HR, 1.27; 95% CI, 0.99-1.64), MI in 560 (6.4%) vs 470 (5.3%; HR, 1.20; 95% CI, 1.06-1.36), stroke in 124 (1.4%) vs 93 (1.1%; HR, 1.33; 95% CI, 1.02-1.74), and stent thrombosis in 328 (3.7%) vs 295 (3.3%; HR, 1.11; 95% CI, 0.89-1.30). The safety end point of major bleeding occurred in 320 individuals in the ticagrelor group (3.6%) vs 285 in the prasugrel group (3.2%; HR, 1.12; 95% CI, 0.96-1.32) (Figure 2, Figure 3, and Table 2).

Figure 1. Study Overview of Screening, Eligibility Assessment, and Propensity Score Matching (PSM)



Specific International Statistical Classification of Diseases, Tenth Revision, German Modification (ICD-10-GM) codes are provided for exclusion criteria. ACS indicates acute coronary syndrome.

The median time interval between ACS diagnosis and the first outpatient prescription of ticagrelor or prasugrel was 7.0 days (IQR, 5.0-9.0 days; mean [SD], 7.2 [2.7] days) vs 7.0 days (IQR, 5.0-8.0 days; mean [SD], 7.0 [2.6] days). Within this period, in-hospital mortality among individuals with ACS within the insurance claims database was 1675 of 78 545 (2.1%).

The on-treatment analysis also found that ticagrelor was significantly associated with inferior outcomes for the primary end point (HR, 1.14; 95% CI, 1.03-1.28) (eTable 6 in Supplement 1). When also adjusting the analysis for age-adjusted doses (5 mg of prasugrel after age 75 years), the median on-treatment follow-up for the ticagrelor group was 11.0 months (IQR, 11.0-12.0 months; mean [SD], 10.6 [2.2] months), while for the prasugrel group, it was 12.0 months (IQR, 12.0-12.0 months; mean [SD], 11.2 [1.9] months).

Sensitivity analyses confirmed consistent results. Propensity score matching with extended preexposure characteristics (n = 71) showed an association of ticagrelor with more events related to the primary composite end point (HR, 1.25; 95% CI, 1.13-1.38). Results for the negative control outcome of influenza revealed no significant difference between the treatment groups (HR, 0.77; 95% CI, 0.45-1.32). Captured prescription fills for aspirin were comparable in both groups (4755 individuals [53.9%] for ticagrelor vs 4847 [54.9%] for prasugrel) within 14 days of ACS diagnosis.²¹⁻²⁴

When comparing the results with those of IR5, the database study reached regulatory agreement for the primary composite end point, all secondary end points except stroke, and the safety end point. Concordance in estimate agreement was observed across all end points between the database evidence and IR5 results (eFigure 1 and eTable 5 in Supplement 1).

Table 1. Baseline Characteristics Before and After Propensity Score Matching

Preexposure characteristic ^a	Before propensity score matching			After propensity score matching		
	Ticagrelor (n = 14 681) ^b	Prasugrel (n = 13 042) ^b	SMD	Ticagrelor (n = 8821) ^b	Prasugrel (n = 8821) ^b	SMD
Age, mean (SD), y	67.5 (12.0)	60.2 (10.5)	0.648	63.1 (11.7)	63.0 (10.0)	0.007
Sex						
Female	4690 (31.9)	2966 (22.7)	-0.208	2292 (26.0)	2316 (26.3)	-0.006
Male	9991 (68.1)	10 076 (77.3)	0.208	6529 (74.0)	6505 (73.7)	0.006
Cardiovascular risk factors						
Diabetes	5412 (36.9)	3993 (30.6)	0.132	2941 (33.3)	2926 (33.2)	0.004
Use of insulin	1250 (8.5)	817 (6.3)	0.086	626 (7.1)	624 (7.1)	0.001
Current smoker	2919 (19.9)	3748 (28.7)	0.208	2213 (25.1)	2196 (24.9)	0.004
Hypertension	12 371 (84.3)	9834 (75.4)	0.222	7036 (79.8)	7087 (80.3)	-0.014
Hyperlipidemia	11 609 (79.1)	9648 (74.0)	0.121	6719 (76.2)	6763 (76.7)	-0.012
Medical history						
Myocardial infarction	2359 (16.1)	1777 (13.6)	0.069	1294 (14.7)	1286 (14.6)	0.003
PCI	586 (4.0)	319 (2.5)	0.088	250 (2.8)	263 (3.0)	0.009
CABG	64 (0.4)	15 (0.1)	0.061	16 (0.2)	14 (0.2)	0.006
Comorbidities						
Chronic kidney disease	2765 (18.8)	1362 (10.4)	0.239	1128 (12.8)	1139 (12.9)	-0.004
Obesity	3659 (24.9)	3062 (23.5)	0.034	2169 (24.6)	2111 (23.9)	0.015
ACS diagnosis at admission						
Unstable angina	1317 (9.00)	706 (5.4)	0.138	655 (7.4)	636 (7.2)	0.007
NSTEMI	7261 (49.5)	3656 (28.0)	0.451	3314 (37.6)	3244 (36.8)	0.003
STEMI	6103 (41.6)	8680 (66.6)	0.518	4852 (55.0)	4941 (56.0)	-0.007
Treatment strategy						
PCI	14 118 (96.2)	12 897 (98.9)	0.176	8694 (98.6)	8684 (98.4)	0.009
CABG	122 (0.8)	15 (0.1)	0.104	17 (0.2)	15 (0.2)	0.005
Conservative therapy	441 (3.0)	130 (1.0)	0.144	110 (1.2)	122 (1.4)	-0.012

Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SMD, standardized mean difference; STEMI, ST-segment elevation myocardial infarction.

^a Preexposure characteristics were measured in the 1 year prior to the ACS event.
^b Data are presented as number (percentage) of participants unless otherwise indicated.

In the subgroup with STEMI, the primary end point occurred in 451 of 4852 individuals in the ticagrelor group (9.3%) vs 338 of 4941 in the prasugrel group (6.8%; HR, 1.38; 95% CI, 1.20-1.59), with comparable bleeding rates (HR, 1.03; 95% CI, 0.82-1.30) (Table 2 and eFigures 2 and 3 in Supplement 1). In the NSTEMI subgroup, the primary end point rates were 321 of 3314 (9.7%) for the ticagrelor group and 297 of 3244 (9.2%) for the prasugrel group (HR, 1.04; 95% CI, 0.89-1.23), while there was no difference in the rate of bleeding (HR, 1.26; 95% CI, 0.99-1.61) (Table 2). In the subgroup with UA, there were no statistically significant differences observed for the primary end point, which occurred in 43 of 655 individuals (6.6%) in the ticagrelor group vs 28 of 636 (4.4%) in the prasugrel group (HR, 1.50; 95% CI, 0.94-2.44). No significant difference was observed between ticagrelor and prasugrel for the safety end point (HR, 0.98; 95% CI, 0.56-1.68) in the subgroup with UA (Table 2).


Discussion

In the setting of routine care, this cohort study found that prasugrel was associated with a significantly lower incidence of the primary composite end point (all-cause mortality, MI, or stroke) compared with ticagrelor in individuals discharged from the hospital after undergoing an invasive treatment strategy for ACS, particularly those with STEMI. In contrast, no significant difference in major bleeding between prasugrel and ticagrelor was found.

While there is no perfect emulation of an RCT with secondary data, the present study demonstrated complementary evidence for IR5¹ after closely emulating its research question, akin to the target trial framework.^{25,26} After appropriate methods were applied, meeting 11 of 12 agreement metrics provided confidence in the validity of the results. The deviation in 1 agreement metric may have been attributable to the augmented power of the present study.

The present study had sufficient power to analyze the distinct ACS components that were underpowered in IR5.^{27,28} In individuals with STEMI, prasugrel was associated with a 38% relative risk reduction for the primary end point compared with ticagrelor, supporting use of prasugrel for STEMI, while both drugs were associated with similar risk among individuals with NSTEMI and UA. Thus, this study may have implications for the choice of P2Y₁₂ receptor inhibitor for ACS components, particularly in patients with STEMI, as indirectly supported by data from other trials.^{14,15} In PLATO, ticagrelor compared with clopidogrel did not significantly reduce ischemic events in a predefined subgroup analysis of 7544 patients with STEMI (HR, 0.87; 95% CI, 0.75-1.01).¹⁴ In contrast, TRITON-TIMI 38 showed that prasugrel significantly reduced ischemic events compared

Figure 2. Cumulative Incidence of the Primary End Point and Safety End Point at 1 Year



The Kaplan-Meier curves show the cumulative incidence of the primary composite end point (all-cause mortality, myocardial infarction [MI], or stroke) and of the safety outcome, major bleeding. Aalen-Johansen estimates are provided for bleeding considering competing risk of death.


with clopidogrel in a smaller cohort of 3534 patients with STEMI (HR, 0.79; 95% CI, 0.65-0.97).¹⁵ Though not direct head-to-head comparisons, these results also suggest that prasugrel may more effectively reduce ischemic events in STEMI, potentially due to its irreversible platelet inhibition, which is especially important in patients with STEMI undergoing an interventional strategy.^{29,30}

While our results suggest a possible advantage of prasugrel for the treatment of ACS in routine care, particularly in STEMI, 2 network meta-analyses of 12³¹ and 23³² heterogeneous RCTs (including IR5,¹ PRAGUE-18,^{2,3} PLATO,¹⁴ and TRITON-TIMI 38¹⁵) found no significant difference between the 2 P2Y12 receptor inhibitors, potentially due to differences in study design, populations, and follow-up.^{31,32} In contrast, another large database study showed a numerically lower event rate for prasugrel vs ticagrelor for multiple end points, including MI, at 180 days, with the effect differences becoming more pronounced over time.³³

Limitations

By design, this study has inherent limitations. First, we recognize important design differences between this study and IR5.¹ Whereas randomization in IR5 took place in hospital before the invasive treatment strategy was performed, the present study omitted the in-hospital period by setting time 0 as the first observed outpatient initiation of ticagrelor or prasugrel after ACS treatment, as in-hospital medication data were not available. Consequently, early events were not captured, which

Figure 3. Cumulative Incidence of Secondary End Points at 1 Year



The Kaplan-Meier curves show the cumulative incidence of the secondary end points—individual components of the primary end point (all-cause mortality, myocardial infarction [MI], and stroke) as well as stent thrombosis. Aalen-Johansen estimates are provided for MI, stroke, and stent thrombosis considering competing risk of death.

may explain why we did not observe higher event rates. To address discrepancies in early event capture, we calculated in-hospital mortality in the entire cohort with ACS regardless of subsequent treatment. By adding these data to the mortality observed in the primary study cohort, we found a mortality rate comparable to those in IR5 for both ticagrelor (3.6%) and prasugrel (3.3%).¹ Furthermore, in PRAGUE-18,^{2,3} which had its primary end point at 7 days after ACS, there was no difference in in-hospital events between both treatment groups. We could not study the role of aspirin in the comparative effectiveness of the P2Y12 receptor inhibitors, as the database used does not reliably capture over-the-counter drug use. However, captured prescription fills for aspirin were comparable in both groups, and dual-antiplatelet therapy was recommended by the European Society of Cardiology throughout the study period.²¹⁻²⁴

Second, the observational nature of our study limits its ability to infer causality due to the potential of confounding. To address this, we used 1:1 propensity score matching supplemented by a sensitivity analysis on an expanded set of predefined preexposure characteristics, which affirmed the consistency of the results. Similar incidence rates in the negative control outcome of influenza further support the minimal impact of residual confounding.

Third, although both ticagrelor and prasugrel had equivalent regulatory approvals and guideline recommendations (class I, level B)²¹⁻²⁴ during the study period, potential confounding by indication cannot be entirely ruled out. However, the choice between the drugs was primarily at the discretion of the treating physician, rather than based on specific indications. To further minimize potential bias, we incorporated year of ACS onset as a variable in the propensity score to adjust for temporal variations in clinical practice.

Fourth, while administrative codes offer an objective method of classifying medical concepts, their accuracy depends on coding precision and physician judgment. This may particularly affect conditions with subjective diagnostic criteria, such as UA and bleeding, but is less likely to impact conditions with clear diagnostic definitions, such as STEMI or NSTEMI, that have demonstrated high predictive power in administrative claims.^{34,35} Misclassification of outcomes is expected to be nondifferential between groups, minimizing bias in comparative analyses.

Table 2. Study End Points

Outcome	Participants, No. (%)		HR (95% CI)
	Ticagrelor	Prasugrel	
Any ACS			
Total, No.	8821	8821	NA
Primary end point ^a	815 (9.2)	663 (7.5)	1.24 (1.12-1.37)
All-cause mortality	135 (1.5)	106 (1.2)	1.27 (0.99-1.64)
Myocardial infarction	560 (6.4)	470 (5.3)	1.20 (1.06-1.36)
Stroke	124 (1.4)	93 (1.1)	1.33 (1.02-1.74)
Stent thrombosis	328 (3.7)	295 (3.3)	1.11 (0.89-1.30)
Safety end point ^b	320 (3.6)	285 (3.2)	1.12 (0.96-1.32)
STEMI			
Total, No.	4852	4941	NA
Primary end point ^a	451 (9.3)	338 (6.8)	1.38 (1.20-1.59)
Safety end point ^b	147 (3.0)	146 (3.0)	1.03 (0.82-1.30)
NSTEMI			
Total, No.	3314	3244	NA
Primary end point ^a	321 (9.7)	297 (9.2)	1.04 (0.89-1.23)
Safety end point ^b	147 (4.4)	113 (3.5)	1.26 (0.99-1.61)
Unstable angina			
Total, No.	655	636	NA
Primary end point ^a	43 (6.6)	28 (4.4)	1.50 (0.94-2.44)
Safety end point ^b	26 (4.0)	26 (4.1)	0.98 (0.56-1.68)

Abbreviations: ACS, acute coronary syndrome; HR, hazard ratio; NA, not applicable; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

^a All-cause mortality, myocardial infarction, or stroke.

^b Major bleeding.

Fifth, the reliance on a German health claims database may limit the generalizability of our results to other ethnicities and health care systems. However, the database used reflects German routine care, and the Bavarian population closely approximates the Central-Western European population studied in IR5.

Conclusions

In this cohort study of 17 642 individuals discharged after an invasive treatment strategy for ACS, prasugrel was associated with significantly lower event rates compared with ticagrelor in the primary composite outcome of all-cause mortality, MI, or stroke, without excess bleeding. These findings support the superior effectiveness of prasugrel over ticagrelor observed in IR5.¹ The database study also allowed for robust analyses of ACS subtypes to complement underpowered RCT results. Prasugrel was associated with better outcomes compared with ticagrelor in individuals with STEMI, whereas no significant differences were observed in individuals with NSTEMI or UA. Overall, this study supports guideline recommendations preferring prasugrel over ticagrelor in patients with acute MI who are intended to undergo an invasive treatment strategy.

ARTICLE INFORMATION

Accepted for Publication: September 27, 2024.

Published: December 2, 2024. doi:10.1001/jamanetworkopen.2024.48389

Correction: This article was corrected on January 17, 2025, to fix data errors in the Results, Table 2, Figures 2 and 3, and eTable 5 in Supplement 1.

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2024 Krüger N et al. *JAMA Network Open*.

Corresponding Authors: Heribert Schunkert, MD (schunkert@dhm.mhn.de), and Moritz von Scheidt, MD (moritz.scheidt@tum.de), Department of Cardiology, German Heart Center Munich, Technical University of Munich, Lazarettstr 36, Munich 80636, Germany.

Author Affiliations: Department of Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany (Krüger, Krefting, Kessler, Schmieder, Starnecker, Dutsch, Graesser, Meyer-Lindemann, Storz, Pugach, Frieß, Chen, Sager, Wiebe, Kufner, Xhepa, Joner, Trenkwalder, Gueldener, Kastrati, Cassese, Schunkert, von Scheidt); Deutsches Zentrum für Herz-Kreislauf-Forschung, Partner Site Munich Heart Alliance, Munich, Germany (Krüger, Krefting, Kessler, Schmieder, Starnecker, Dutsch, Graesser, Meyer-Lindemann, Chen, Sager, Wiebe, Joner, Trenkwalder, Kastrati, Schunkert, von Scheidt); Department of Internal Medicine I, Cardiology, University Hospital Augsburg, University of Augsburg, Augsburg, Germany (Bongiovanni); School of Electronic Engineering and Computer Science, Queen Mary University of London, London, United Kingdom (Manea); Institute of General Practice and Family Medicine, LMU University Hospital, LMU Munich, Munich, Germany (Dreischulte); Allgemeine Ortskrankenkasse Bayern, Munich, Germany (Offenborn, Krase).

Author Contributions: Drs Krüger and Krefting had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Krüger and Krefting contributed equally.

Concept and design: Krüger, Krefting, Kessler, Starnecker, Graesser, Meyer-Lindemann, Storz, Manea, Sager, Xhepa, Schunkert, von Scheidt.

Acquisition, analysis, or interpretation of data: Krüger, Krefting, Kessler, Schmieder, Dutsch, Pugach, Friess, Chen, Bongiovanni, Dreischulte, Offenborn, Krase, Wiebe, Kufner, Joner, Trenkwalder, Gueldener, Kastrati, Cassese, von Scheidt.

Drafting of the manuscript: Krüger, Krefting, Schmieder, Sager, Gueldener, Cassese, Schunkert, von Scheidt.

Critical review of the manuscript for important intellectual content: Krüger, Krefting, Kessler, Starnecker, Dutsch, Graesser, Meyer-Lindemann, Storz, Pugach, Friess, Chen, Bongiovanni, Manea, Dreischulte, Offenborn, Krase, Sager, Wiebe, Kufner, Xhepa, Joner, Trenkwalder, Kastrati, Cassese, von Scheidt.

Statistical analysis: Krüger, Krefting, Schmieder, Dutsch, Pugach, Friess, Bongiovanni, Manea.

Obtained funding: Kessler, Schunkert.

Administrative, technical, or material support: Krüger, Krefting, Kessler, Schmieder, Starnecker, Meyer-Lindemann, Storz, Offenborn, Krase, Sager, Wiebe, Joner, Trenkwalder, Gueldener, Kastrati, Schunkert, von Scheidt.

Supervision: Kessler, Wiebe, Xhepa, Cassese, Schunkert, von Scheidt.

Conflict of Interest Disclosures: Dr Krüger reported receiving grants from the German Heart Foundation and the Deutsches Zentrum für Herz-Kreislauf-Forschung outside the submitted work. Dr Kessler reported receiving personal fees from Abbott, Translumina, Bristol Myers Squibb, and AstraZeneca and grants from the German Research Foundation, European Research Council, and Corona Foundation outside the submitted work and having patents PCT/EP2021/053116 and US 2023/137816 pending. Dr Graesser reported receiving grants from the Clinician Scientist Programme outside the submitted work. Dr Sager reported receiving research grants from the German Research Foundation, Else Kröner-Fresenius-Stiftung, and the European Research Council outside the submitted work. Dr Wiebe reported receiving speaker fees from AstraZeneca and Translumina and an institutional research grant and speaker fees from Abbott outside the submitted work. Dr Kufner reported receiving personal fees from AstraZeneca, BMS, Boehringer Ingelheim, Bentley, and Translumina outside the submitted work. Dr Joner reported receiving personal fees from Abbott, AlchiMedics, AstraZeneca, Biotronik, Boston Scientific, Cardiac Dimensions, Edwards, Medtronic, ReCor, Shockwave, TRiCares, and Veryan and grants from Boston Scientific outside the submitted work. Dr Schunkert reported receiving honoraria from Amarin, Amgen, AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Medtronic, MSD Sharp & Dohme, Novartis, Pfizer, Sanofi Aventis, Servier, and Synlab outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by grant DMB-1805-0001, within the framework of DigiMed Bayern, from the Bavarian State Ministry of Health, Care and Prevention and by grant 1530/891 02 from the Bavarian State Ministry of Science and the Arts through the DHM-MSRM Joint Research Center. The work was also supported by grants ZF4590201BA8 from the German Federal Ministry of Economics and Energy in its scheme of ModulMax, MIRACLE 101115381 from the Horizon Europe Framework Programme (HORIZON) of the European Commission, 01ZX1904A from the German Federal Ministry of Education and Research (BMBF) within the framework of COMMITMENT, DZHK-BHF: 81X2600522 from the British Heart Foundation-Deutsches Zentrum für Herz-Kreislauf-Forschung collaboration, and PlaQOmics: 18CVD02 from the Leducq Foundation for Cardiovascular Research.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The members of the DigiMed Bayern Consortium are listed in [Supplement 2](#).

Data Sharing Statement: See [Supplement 3](#).

Additional Contributions: We thank AOK Bayern and all individuals donating cardiovascular-relevant data for the realization of this study.

REFERENCES

1. Schüpke S, Neumann FJ, Menichelli M, et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. *N Engl J Med*. 2019;381(16):1524-1534. doi:10.1056/NEJMoA1908973
2. Motovska Z, Hlinomaz O, Kala P, et al; PRAGUE-18 Study Group. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. *J Am Coll Cardiol*. 2018;71(4):371-381. doi:10.1016/j.jacc.2017.11.008
3. Motovska Z, Hlinomaz O, Miklik R, et al; PRAGUE-18 Study Group. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. *Circulation*. 2016;134(21):1603-1612. doi:10.1161/CIRCULATIONAHA.116.024823
4. Byrne RA, Rossello X, Coughlan JJ, et al; ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. *Eur Heart J*. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191
5. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACCP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. *Circulation*. 2016;134(10):e123-e155. doi:10.1161/CIR.0000000000000404

6. US Food & Drug Administration. PDUFA VI: fiscal years 2018-2022. Updated October 3, 2022. Accessed January 17, 2024. <https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vi-fiscal-years-2018-2022>
7. Deutsches Bundesgesundheitsministerium. Gesundheitsdatennutzungsgesetz (GDNG). Published December 22, 2023. Accessed January 17, 2024. <https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html>
8. 21st Century Cures Act, HR 34, 114th Cong (2015-2016). Accessed January 15, 2024. <https://www.congress.gov/bill/114th-congress/house-bill/34>
9. US Food & Drug Administration. Framework for FDA's Real-World Evidence Program. December 2018. Accessed October 20, 2023. <https://www.fda.gov/media/120060/download>
10. European Medicines Agency. Real-world evidence framework to support EU regulatory decision-making. 2023. Accessed January 19, 2024. https://www.ema.europa.eu/system/files/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained_en.pdf
11. Shah RP, Shafiq A, Hamza M, et al. Ticagrelor versus prasugrel in patients with acute coronary syndrome: a systematic review and meta-analysis. *Am J Cardiol*. 2023;207:206-214. doi:10.1016/j.amjcard.2023.08.117
12. Imbens GW, Rubin DB. *Causal inference in statistics, social, and biomedical sciences*. Cambridge University Press; 2015. doi:10.1017/CBO9781139025751
13. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. *J Educ Psychol*. 1974;66(5):688-701. doi:10.1037/h0037350
14. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361(11):1045-1057. doi:10.1056/NEJMoa0904327
15. Montalescot G, Wiviott SD, Braunwald E, et al; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet*. 2009;373(9665):723-731. doi:10.1016/S0140-6736(09)60441-4
16. Federal Institute for Drugs and Medical Devices. Observational Bavarian Health Insurance Registry (OBSERVABLE)—improving prevention, prediction and treatment in cardiovascular disease. 2021. Accessed January 18, 2024. <https://drks.de/search/en/trial/DRKS00024016>
17. Franklin JM, Pawar A, Martin D, et al. Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project. *Clin Pharmacol Ther*. 2020;107(4):817-826. doi:10.1002/cpt.1633
18. Davidson-Pilon C. lifelines: survival analysis in Python. *J Open Source Softw*. 2019;4(40):1317. doi:10.21105/joss.01317
19. Van Rossum GD. *Python Language Reference*, release 3.11.3. CreateSpace; 2009.
20. R. Version 4.1.2. R Project for Statistical Computing; 2018. Accessed January 17, 2024. <https://www.R-project.org/>
21. Roffi M, Patrono C, Collet JP, et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320
22. Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393
23. Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575
24. Hamm CW, Bassand JP, Agewall S, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2011;32(23):2999-3054. doi:10.1093/eurheartj/ehr236
25. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol*. 2016;183(8):758-764. doi:10.1093/aje/kwv254

26. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol*. 2016;79:70-75. doi:10.1016/j.jclinepi.2016.04.014
27. Valina C, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol*. 2020;76(21):2436-2446. doi:10.1016/j.jacc.2020.09.584
28. Aytekin A, Ndrepepa G, Neumann FJ, et al. Ticagrelor or prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Circulation*. 2020;142(24):2329-2337. doi:10.1161/CIRCULATIONAHA.120.050244
29. Bongiovanni D, Schreiner N, Gosetti R, et al. Immature platelet fraction predicts adverse events in patients with acute coronary syndrome: the ISAR-REACT 5 reticulated platelet substudy. *Arterioscler Thromb Vasc Biol*. 2023;43(2):e83-e93. doi:10.1161/ATVBAHA.122.318614
30. Coughlan JJ, Aytekin A, Lahu S, et al. Ticagrelor or prasugrel for patients with acute coronary syndrome treated with percutaneous coronary intervention: a prespecified subgroup analysis of a randomized clinical trial. *JAMA Cardiol*. 2021;6(10):1121-1129. doi:10.1001/jamacardio.2021.2228
31. Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. *Circulation*. 2020;142(2):150-160. doi:10.1161/CIRCULATIONAHA.120.046786
32. De Filippo O, Piroli F, Bruno F, et al. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. *BMJ Evid Based Med*. 2024;29(3):171-186. doi:10.1136/bmjebm-2023-112476
33. Kumar A, Lutsey PL, St Peter WL, et al. Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study. *Clin Pharmacol Ther*. 2023;113(2):401-411. doi:10.1002/cpt.2797
34. Platzbecker K, Voss A, Reinold J, et al. Validation of algorithms to identify acute myocardial infarction, stroke, and cardiovascular death in German health insurance data. *Clin Epidemiol*. 2022;14:1351-1361. doi:10.2147/CLEP.S380314
35. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. *PLoS One*. 2014;9(3):e92286. doi:10.1371/journal.pone.0092286

SUPPLEMENT 1.

eTable 1. Diagnoses, Procedures, and Medication List

eTable 2. Eligibility Criteria Emulation

eTable 3. Baseline Preexposure Variables for Propensity Score Matching

eTable 4. Extended Preexposure Variables for Propensity Score Matching

eTable 5. Detailed Comparison of Results Between Database Study and IR5

eTable 6. Sensitivity Analyses

eFigure 1. Comparison of Primary and Safety End Points Between Database Study and IR5

eFigure 2. STEMI Subgroup Analysis—Primary End Point

eFigure 3. STEMI Subgroup Analysis—Safety End Point

SUPPLEMENT 2.

DigiMed Bayern Consortium

SUPPLEMENT 3.

Data Sharing Statement